5 completed. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
Follow IDX184: new trials by email Literature Review of IDX184 trials Research Report on IDX184
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) IDX184, Peginterferon alfa-2a (Peg-IFN), Ribavirin (RBV) - Hepatitis C, Chronic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 68 | 2011-07-01 | 2015-02-06 |
| A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002) IDX320, IDX184, IDX184 placebo - Chronic Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2010-06-01 | 2016-01-22 |
| Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) IDX184, Placebo, Peginterferon alfa-2a (Peg-IFN) - Chronic Hepatitis C Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 81 | 2009-11-01 | 2015-04-23 |
| Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects IDX184 - Chronic Hepatitis C (HCV) | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 41 | 2008-12-01 | 2016-08-19 |
| Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) IDX184, Placebo - Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 48 | 2008-07-01 | 2015-04-23 |
Hepatitis C (4) · Hepatitis C, Chronic (4)